embolization of the basilar tip aneurysm with a cobalt platinum coronary bare metal stent. Though it did not conform well to the vessel wall due to its rigid characteristics, it provided good neck coverage and allowed successful coil embolization of the aneurysm. 10-month repeat cerebral angiogram showed no residual filling of the basilar aneurysm or in-stent stenosis.

Discussion Titanium allergy is an under recognized entity. Titanium allergies are documented in the literature, with proposed rates in the general population of 0.9-7.9%. Allergy to titanium oxides, as in our patient, is the rarest. Titanium is a component in nitinol-based devices in combination with nickel and surgical clips are also made of titanium. Thus, treatment options for wide necked aneurysms are limited. Allergic reactions to titanium are not well understood, but have been reported as type IV hypersensitivity reactions manifested as cutaneous rashes or delayed-onset in-stent stenosis in cardiac stenting. Neurological reactions to titanium allergies are less well documented. As many implantable medical devices contain various metal alloys including titanium, care should be taken before implanting such devices, including utilizing devices composed of alternative materials in those with known titanium allergies to prevent local or systemic allergic responses.

Disclosures J. Santucci: None. A. Mahapatra: None. M. Hussain: None.

E-063 NOVEL USE OF AN EKOSONIC™ (EKOS) ENDOVASCULAR SYSTEM AS RESCUE THERAPY IN THE TREATMENT OF A HIGHLY REFRACTORY CEREBRAL VENOUS SINUS THROMBOSIS

N Vivelo*, R Ryan, R Sanchez-Mejia. Virginia Mason, Seattle, WA

Introduction Endovascular treatment for cerebral venous sinus thrombosis (CVST) is typically considered a rescue therapy in management of patients with clinical deterioration or progression of intracranial hemorrhage/venous infarct despite systemic anticoagulation. Morbidity and mortality are high in this challenging population. Current endovascular treatment options include direct aspiration or stent retriever thrombectomy, balloon thrombectomy, balloon angioplasty and stenting, and AngioJet device (MEDRAD Inc), with optimum therapy not well defined and many cases refractory to intervention. We describe a novel treatment in a highly refractory case.

Methods We report a 23-year-old female, with no past medical history, who suffered spontaneous CVST involving the entire superior sagittal sinus, left transverse and sigmoid sinus, and jugular vein. After worsening neurologic exam despite heparin therapy, initial endovascular approach was used to restore venous flow and required mechanical and chemical thrombectomy, angioplasty and stenting. During post-procedure anti-thrombotic therapy she had expansion of venous hemorrhage requiring minimally invasive surgical evacuation and holding blood thinners. Subsequent stent thrombosis developed which was treated with repeat endovascular therapy and use of an EKOS catheter deployed in the venous sinuses for 24 hours with constant TPA infusion and ultrasonic energy. This case report reviews multimodality CVST treatment, including the feasibility of EkoSonic™ (EKOS) Endovascular System for rescue therapy.
Results The use of the EKOS catheter and TPA infusion restored sufficient venous drainage and ultimately the patient developed good collateral flow. The result was an excellent six-month post-operative neurologic outcome.

Conclusion CVST can be refractory to existing endovascular treatment options. We describe the use of an EKOS catheter, traditionally used in peripheral vascular and pulmonary emboli cases, as rescue therapy in a cerebrovascular case where traditional treatment options failed. Further evaluation is warranted to clarify its safety and efficacy versus other therapeutic modalities.

Disclosures N. Vivelio: None. R. Ryan: None. R. Sanchez-Mejia: None.

E-064 SURPASS EVOLVE FLOW DIVERSION FOR EMBOLIZATION OF UNRUPTURED INTRACRANIAL ANEURYSMS: EARLY EXPERIENCE OF A SINGLE TERTIARY CENTER


10.1136/neurintsurg-2021-SNIS.159

Introduction Since initially developed, flow-diverting devices for intracerebral endoluminal reconstruction have rapidly evolved and multiple devices now exist, differing in materials and design. Recently, the Stryker Surpass Evolve flow-diverter (FD) has been approved as a 64-wire cobalt-chromium device with improved ease of deployment, flexibility and conformability compared to its predecessor.

Objective To summarize the clinical applications and procedural outcomes of patients who underwent Surpass Evolve FD embolization of an unruptured intracranial aneurysm at a tertiary high-volume single center

Methods The first Surpass Evolve FD was deployed at our institution on August 31, 2020. All consecutive patients who presented since this date with a symptomatic or asymptomatic unruptured intracranial aneurysm and were treated with a Surpass Evolve FD were included. Patients with a ruptured intracranial aneurysm were excluded. Demographic and clinical features, antithrombotic therapy, aneurysm features, access, procedural factors and outcome, and post-procedural neurologic status were extracted from our departmental neurointerventional database and electronic medical records. Follow-up cerebral angiograms were also reviewed. Summary statistics included frequencies, and measures of central tendency and dispersion as appropriate.

Results Since Aug 31, 2020, 32 patients underwent embolization of an unruptured intracranial aneurysm with the Surpass Evolve, and have been followed for a mean of 118.9 (SD 62.3) days. Mean age at intervention was 62.5 (13.4) years, and 25 (78%) were female. In 27 (84%) patients, a native aneurysm was flow-diverted, and in 5 (16%) patients, FD was performed for a recurrent aneurysm. Distribution of aneurysm location was: ICA 21 (66%), ACA 2 (6%), AComm 2 (6%), and posterior fossa 7 (22%). Mean aneurysm size was 8.8 (4.7) mm. Access was radial in 23 (72%), femoral in 8 (25%) and ulnar in 1 (3%). FD was successfully deployed to the target in 31 (97%) of cases. Median FD per patient was one; nine patients had two FD devices placed. Balloon angioplasty or J-wire manipulation was used to enhance apposition in 19 (59%) cases. Neurologic deficits were observed in four patients; 3 (9%) had transient deficits, and 1 (3%) had a permanent deficit. An asymptomatic microperforation was observed in one patient. Migration of the FD was observed in one patient following balloon angioplasty. Early contrast stasis was observed in all patients, and short-term follow-up angiogram for three patients indicated decreased aneurysm size.

Conclusion In our early experience, the Surpass Evolve FD is safe and has an improved ease-of-use profile compared with its Surpass Streamline predecessor. Complication rates are well within the acceptable limits based on published evidence. Serial follow-up angiography will delineate the rate of aneurysm obliteration.

Disclosures L. Verhey: 1; C; Stryker Neurovascular. A. Restrepo Orozco: None. L. Lyons: None. A. Sewell: None. J. Tsai: None. P. Mazaris: None. J. Singer: 2; C; Stryker, Medtronic, Penumbra, Nico, Cerenovus.

E-065 STENTING AND FLOW DIVERSION FOR PEDIATRIC INTRACRANIAL ANEURYSMS


10.1136/neurintsurg-2021-SNIS.160

Background Pediatric intracranial aneurysms (IA) are rare. Literature highlights endovascular treatment yielding favorable outcomes, but long-term follow up outcomes are lacking.

Objective To analyze our institution’s experience of endovascular management of pediatric cerebral aneurysms with long-term follow-up.

Methods In the past decade, 4 male and 2 female patients with nine IA were treated with stenting or flow-diversion. We retrospectively reviewed the radiological, hospital and outpatient clinic charts to document clinical presentation, diagnostic methods, treatment strategies, outcome and long-term follow up for each patient.

Results Headache was the presenting symptom in all of the patients except one, which had a traumatic injury. Two of these patients had a ruptured aneurysm. Two patients had multiple aneurysms - 2 and 3 respectively. The aneurysms were most frequently located in the anterior circulation, with the exception of two basilar. Four of the aneurysms were treated with stenting, while 5 with Pipeline flow-diversion. All cases, except one, had a good outcome after the procedure; the latter having a hemorrhage, requiring hematoma evacuation, and later developing in-stent stenosis, for which balloon angioplasty was done and another pipeline flow-diverter was deployed. Long term imaging follow-up demonstrated no issues regarding the durability of flow-diverters and stents, with 0 modified Rankin Score (mRS) reported for 5 patients and a baseline of 2 for one patient.

Conclusion This series demonstrates the safety and effectiveness of endovascular treatment of pediatric aneurysms, with no issues regarding the durability of flow-diverters and stents at continued long-term follow up.

Disclosures H. Rai: None. F. Almayman: None. M. Waqas: None. A. Kalanovic: None. A. Monteiro: None. A. Baig: None. M. Recker: None. A. Siddiqui: 1; C; NIH/NINDS 1R01NS091075. 4; C; Amnis Therapeutics, Apana Medical, Blink TBI, Buffalo Technology Partners, Cardinal Consultants, CerebroTech Medical Systems, Cognition Medical, Endostream Medical, Imperative Care, International Medi. E. Levy: 2; C;